In addition, a novel ferroptosis inducer, MMRI62, with dual targeting of FTH1 and mutant p53, which induces ferroptosis in pancreatic cancer cells by inducing lysosomal degradation of FTH1 and NCOA4 as well as proteasomal degradation of mutant p53 to improve chemoresistance and control metastasis of cancer cells (145). Here, TP53 is linked to cancer.